Published in J Clin Psychiatry on August 01, 2001
Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J Psychiatry Neurosci (2005) 1.03
Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl) (2005) 1.01
The GABA transporter 1 (SLC6A1): a novel candidate gene for anxiety disorders. J Neural Transm (Vienna) (2008) 0.84
Low-dose tiagabine effectiveness in anxiety disorders. MedGenMed (2004) 0.77
The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord (1999) 2.30
Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2004) 2.12
A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging (2000) 1.78
Transcranial magnetic stimulation in therapy studies: examination of the reliability of "standard" coil positioning by neuronavigation. Biol Psychiatry (2001) 1.65
Antidepressant effects of augmentative transcranial magnetic stimulation: randomised multicentre trial. Br J Psychiatry (2007) 1.63
Social functioning in depression: a review. J Clin Psychiatry (2000) 1.62
Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF. Neurology (2000) 1.60
SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression. Mol Psychiatry (2004) 1.60
Epidemiological evidence for a low abuse potential of zolpidem. Pharmacopsychiatry (2000) 1.53
Combined action of the ACE D- and the G-protein beta3 T-allele in major depression: a possible link to cardiovascular disease? Mol Psychiatry (2002) 1.49
Results of a surveillance programme for patients at high risk of malignant melanoma using digital and conventional dermoscopy. Eur J Cancer Prev (2004) 1.41
[Core symptoms of depression. Effectiveness of antidepressant therapy]. Nervenarzt (2009) 1.40
D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study. J Psychopharmacol (2000) 1.39
Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry (1998) 1.38
Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett (2000) 1.31
Comparative efficacy of antidepressants. Drugs (1992) 1.25
Prefrontal direct current stimulation modulates resting EEG and event-related potentials in healthy subjects: a standardized low resolution tomography (sLORETA) study. Neuroimage (2010) 1.22
Reduced gray matter brain volumes are associated with variants of the serotonin transporter gene in major depression. Mol Psychiatry (2008) 1.20
The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett (2001) 1.20
St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry (1998) 1.17
Neuropsychological profile of adult patients with Niemann-Pick C1 (NPC1) mutations. J Inherit Metab Dis (2006) 1.15
Repetitive transcranial magnetic stimulation (rTMS) in pharmacotherapy-refractory major depression: comparative study of fast, slow and sham rTMS. Psychiatry Res (1999) 1.13
[Psychometric evaluation of the German version of the Barratt Impulsiveness Scale]. Nervenarzt (2008) 1.12
Progesterone induces changes in sleep comparable to those of agonistic GABAA receptor modulators. Am J Physiol (1996) 1.11
Vagus nerve stimulation for depression: efficacy and safety in a European study. Psychol Med (2008) 1.09
The serotonin syndrome scale: first results on validity. Eur Arch Psychiatry Clin Neurosci (1998) 1.08
Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br J Dermatol (1999) 1.07
Dizziness in an older community dwelling population: a multifactorial syndrome. J Nutr Health Aging (2009) 1.07
Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol (1999) 1.07
[Help-seeking behavior and compliance of suicidal patients]. Psychiatr Prax (1984) 1.06
[S3 guidelines on diagnostics and therapy of bipolar disorders: development process and essential recommendations]. Nervenarzt (2012) 1.06
Co-expression of the 5-HT3B serotonin receptor subunit alters the biophysics of the 5-HT3 receptor. Biophys J (2003) 1.06
Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. Neuroreport (2000) 1.06
[Transcranial magnetic stimulation. A diagnostic means from neurology as therapy in psychiatry?]. Nervenarzt (1997) 1.06
Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Mol Psychiatry (2006) 1.04
Heterodimerization between mineralocorticoid and glucocorticoid receptor: a new principle of glucocorticoid action in the CNS. Neuron (1994) 1.04
The SIMA-project: effects of 1 year cognitive and psychomotor training on cognitive abilities of the elderly. Behav Brain Res (1996) 1.03
Binding characteristics of the glucocorticoid receptor in peripheral blood lymphocytes in multiple sclerosis. J Neurol (1999) 1.03
Rediscovery of the case described by Alois Alzheimer in 1911: historical, histological and molecular genetic analysis. Neurogenetics (1997) 1.02
Concentrations of 3 alpha-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiatry (1999) 1.01
Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett (2001) 1.01
Identification and characterization of a 3',5'-cyclic adenosine monophosphate-responsive element in the human corticotropin-releasing hormone gene promoter. Mol Endocrinol (1992) 1.01
What is the optimal serum lithium level in the long-term treatment of bipolar disorder--a review? Bipolar Disord (2008) 1.00
Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs? Neuroscience (2011) 1.00
Progesterone-induced changes in sleep in male subjects. Am J Physiol (1997) 1.00
Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci (2004) 0.98
Allopregnanolone affects sleep in a benzodiazepine-like fashion. J Pharmacol Exp Ther (1997) 0.98
Quality of life in psychiatry: a systematic contribution to construct validation and the development of the integrative assessment tool "modular system for quality of life". Eur Arch Psychiatry Clin Neurosci (2000) 0.96
Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor. Mol Psychiatry (2003) 0.95
Extended survival of patients on long-term lithium treatment. Can J Psychiatry (1995) 0.95
Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch Psychiatr Nervenkr (1970) (1980) 0.95
The psychiatric management of parasuicide patients: a controlled clinical study comparing different strategies of outpatient treatment. Crisis (1987) 0.94
Translocator protein (18 kDa) as a target for novel anxiolytics with a favourable side-effect profile. J Neuroendocrinol (2012) 0.94
The frailty syndrome in general practitioner care: a pilot study. Z Gerontol Geriatr (2010) 0.93
Histopathology and APOE genotype of the first Alzheimer disease patient, Auguste D. Neurogenetics (1998) 0.93
Molecular cloning, functional expression, and pharmacological characterization of 5-hydroxytryptamine3 receptor cDNA and its splice variants from guinea pig. Mol Pharmacol (1998) 0.93
Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner. Mol Psychiatry (2004) 0.93
The neural basis of the P300 potential. Focus on the time-course of the underlying cortical generators. Eur Arch Psychiatry Clin Neurosci (2004) 0.93
The effect of the skull on event-related P300. Clin Neurophysiol (2001) 0.92
Dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS. Neurology (1999) 0.91
Mirtazapine: an inhibitor of cortisol secretion that does not influence growth hormone and prolactin secretion. J Clin Psychopharmacol (2000) 0.91
Neuroactive steroids as modulators of depression and anxiety. Neuroscience (2005) 0.91
Axonal regeneration and neuroinflammation: roles for the translocator protein 18 kDa. J Neuroendocrinol (2012) 0.91
The importance of new antidepressants in the treatment of anxiety/depressive disorders. Pharmacopsychiatry (1999) 0.91
Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry (2001) 0.91
Transcranial direct current stimulation in treatment resistant depression: a randomized double-blind, placebo-controlled study. Brain Stimul (2011) 0.91
Effects of fluoxetine, indomethacine and placebo on 3 alpha, 5 alpha tetrahydroprogesterone (THP) plasma levels in uncomplicated alcohol withdrawal. World J Biol Psychiatry (2000) 0.91
Thalamic volume in first-episode and chronic schizophrenic subjects: a volumetric MRI study. Schizophr Res (2005) 0.91
Region-specific corpus callosum atrophy correlates with the regional pattern of cortical glucose metabolism in Alzheimer disease. Arch Neurol (1999) 0.90
Mood-stabilisers reduce the risk of developing antidepressant-induced maniform states in acute treatment of bipolar I depressed patients. J Affect Disord (2001) 0.90
Effects of treatment with the atypical neuroleptic quetiapine on working memory function: a functional MRI follow-up investigation. Eur Arch Psychiatry Clin Neurosci (2006) 0.90
[Disorders of premorbid social adaptation as a predictor of the 5-year prognosis of schizophrenic psychoses]. Nervenarzt (1984) 0.89
Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology (2001) 0.89